Jon M. Schott
University College London
8 Papers
2 Citations
Jon M. Schott is an academic researcher from University College London. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Revealing Individual Neuroanatomical Heterogeneity in Alzheimer's Disease
Serena Verdi,Seyed Mostafa Kia,Keir X.X. Yong,Duygu Tosun,Jon M. Schott,Andre F. Marquand,James H. Cole +6 more
TL;DR: This work aimed to characterise individual differences and outliers in cortical thickness in patients with Alzheimers disease, people with mild cognitive impairment and cognitively normal controls, and assessed the relationships between cortical thickness heterogeneity and cognitive function, amyloid-beta, tau, ApoE genotype.
Operationalising the Centiloid Scale for florbetapir PET Studies on PET/MR
William Coath,Marc Modat,M. Jorge Cardoso,P. Markiewicz,Christopher A. Lane,Thomas D. Parker,Ashvini Keshavan,Sarah M Buchanan,Sarah E Keuss,Matthew Harris,Ninon Burgos,John Dickson,Anna Barnes,David L. Thomas,Daniel Beasley,I. Malone,Andrew Wong,Kjell Erlandsson,Bernadette A. Thomas,M. SchoÌll,Sebastien Ourselin,M. Richards,Nick C. Fox,Jon M. Schott,David M. Cash +24 more
TL;DR: The results show florbetapir SUVRs acquired on PET/MR scanners can be reliably converted to Centiloid values, and proposes a correction to account for these effects.
AD and its comorbidities: An obstacle to develop a clinically efficient treatment?
June V. Baker,Jon M. Schott +1 more
TL;DR: How some of the most important comorbid conditions accompanying and in some cases mimicking AD impact the development of clinically efficient treatments for AD are discussed.
3
Probing ftd genetics with next-generation sequencing
Carolin Koriath,Gary Adamson,Ron Druyeh,Janna Kenny,Martin N. Rossor,Jon M. Schott,John Collinge,Nick C. Fox,Jon Rohrer,Simon Mead +9 more
TL;DR: A validated 17-gene NGS dementia panel combined with PCR-based assessments of the C9orf72 and PRNP expansions to the UCL FTD DNA cohort and compared with demographic and clinical data to classify mutations by likelihood of pathogenicity.
1
Trajectories of neurodegeneration and seed amplification biomarkers prior to disease onset in individuals at risk of prion disease
Tze How Mok,Akin Nihat,Nour K. Majbour,Danielle Sequeira,Leah Holm-Mercer,Thomas Coysh,Lee Darwent,Matthew Batchelor,Bradley R. Groveman,Cd Orrù,A. Hughson,Amanda Heslegrave,R. Laban,E. Veleva,Ross W. Paterson,Ashvini Keshavan,Jon M. Schott,Imogen Swift,Carolin Heller,J. Rohrer,Alexander Gerhard,Christopher C Butler,J. Rowe,Mario Masellis,Miles D. Chapman,Margaret C. Lunn,Jan Bieschke,P. S. Jackson,Henrik Zetterberg,Byron Caughey,Peter Rudge,John Collinge,Simon Mead +32 more
TL;DR: In this article , the authors report the accrual of a longitudinal biofluid resource in patients, controls and healthy people at-risk of prion diseases, to which ultrasensitive techniques such as real-time quaking-induced conversion (RT-QuIC), and single molecule array (Simoa) digital immunoassays were applied for preclinical biomarker discovery.
1